image description

Tag: Dr. William Stohl

Catalyzing Research

First Lupus Nephritis Drug Approved In December of 2020, lupus research attained another major milestone-one which stemmed from a critical investigation funded by our organization. Now, with the FDA’s approval, belimumab (Benlysta®) can be used as a therapeutic for lupus nephritis. “An effective treatment developed specifically for lupus nephritis has been desperately needed,” commented Lupus […] Read More

New Study Shows Benlysta Alters B Cells in People with Lupus

August 21, 2019 Newly published research found that belimumab (Benlysta®) effectively reduced the number of B cells, a type of white blood cell that makes antibodies.  According to the prescribing information, belimumab is “a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of patients aged 5 years and older with active, autoantibody positive, systemic lupus […] Read More